Henry Schein, Inc. (HSIC) is a major global healthcare products and services provider. With a market cap of $8.4 billion, the New York-based company offers supplies, equipment, pharmaceuticals, and value-added solutions to dental and medical practitioners through a large distribution network. HSIC stock has underperformed the S&P 500 but outpaced the Health Care Select Sector SPDR Fund over the past year.

HSIC shares surged 10.8% after exceeding market expectations in Q3 earnings. Revenue reached $3.34 billion, up 5.2% YoY, with solid segment performance. Non-GAAP EPS increased 13.1% to $1.38, and adjusted EBITDA rose to $295 million. Management raised full-year 2025 non-GAAP EPS outlook to $4.88–$4.96, expecting 3–4% sales growth.

Analysts anticipate HSIC’s adjusted EPS to grow 3.6% YoY to $4.91 for fiscal year 2025. The consensus rating among 15 analysts is a “Moderate Buy,” with five “Strong Buy” ratings, nine “Holds,” and one “Strong Sell.” This is an improvement from three months ago, with four “Strong Buy” ratings on the stock.

Leerink Partners analyst Michael Cherny maintained a “Hold” rating on Henry Schein on Oct. 14 and kept a $71 price target.

Read more at Yahoo Finance: Do Wall Street Analysts Like Henry Schein Stock?